### FORM 9

# NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

## (or securities convertible or exchangeable into listed securities 1)

Name of Listed Issuer:	Symbol(s):				
Ikänik Farms Inc. (the "Issuer").	IKNK.U				
Date: June 16, 2021 Is this an updating or amending Notice	e:X Yes □ No				
If yes provide date(s) of prior Notices: <u>June 10, 2021</u>					
Issued and Outstanding Securities of Issuer Prior to Issuance: <u>96,471,825</u> (146,441,125 on an "as-converted" basis in the case of the Issuer's Series A Multiple Voting Shares).					
Pricing					
Date of news release announcing proposed issuance: <u>Disc</u> dated as at March 30, 2021 on pages 21 and 22.					
Date of confidential request for price protection: N/A					
Closing Market Price on Day Preceding the news release: $\underline{\mathbf{N}}$	<u>l/A</u> or				
Day preceding request for price protection: N/A					
Closing					
Number of securities to be issued: 6,000,000 (with an additive Voting Shares ("Shares") to be issued upon satisfaction of cartes below).					
Issued and outstanding securities following issuance: 102,4 "as-converted" basis in the case of the Issuer's Series A Mu					
Instructions:					
<ol> <li>For private placements (including debt settlement), com Part 1 of this form.</li> </ol>	plete tables 1A and 1B in				
<ol> <li>Complete Table 1A – Summary for all purchasers, exclusion</li> <li>8.</li> </ol>	iding those identified in Item				
3. Complete Table 1B – Related Persons only for Related	Persons				
4. If shares are being issued in connection with an acquisit or to raise funds for a cash acquisition) please proceed	`				

5.	An issuance of non-convertible debt does not have to be reported unless it is a
	significant transaction as defined in Policy 7, in which case it is to be reported on
	Form 10 – Notice of Proposed Transaction

6.	Post the completed Form 9 to the CSE website in accordance with <i>Policy 6</i> –
	Distributions. In addition, the completed form must be delivered to
	listings@thecse.com with an appendix that includes the information in Table 1B for
	ALL placees.

#### Part 1. Private Placement

#### [Intentionally Deleted.]

#### Part 2. Acquisition

- 1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: All of the issued and outstanding shares (the "D9C Shares") in the capital of D9C Mexico S.A. de C.V. ("D9C"). D9C is involved in the importation and stabilization process of cannabis cultivars.
- \_\_\_\_\_.
- 2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: Pursuant to the terms of a stock transfer agreement (the "Stock Transfer Agreement") dated December 14, 2020 among a predecessor to the Issuer, D9C and the former shareholders of D9C (the "Transferring Shareholders") as further described in the Listing Statement of the Issuer dated March 30, 2021, the Transferring Shareholders are to transfer their shares of D9C (representing all of the issued and outstanding shares in the capital of D9C to the Issuer upon the satisfaction of certain conditions as set out in the Stock Transfer Agreement. In exchange for the D9C Shares, the Issuer is to issue an aggregate of 10,000,000 Shares to the Transferring Shareholders in three tranches upon the satisfaction of the conditions set forth in the Stock Transfer Agreement. As D9C has satisfied the first set of conditions, the Issuer will issue 6,000,000 Shares to the Transferring Shareholders and the Transferring Shareholders will transfer all of the issued and outstanding D9C Shares to the Issuer.

The remaining 4,000,000 Shares will be issued to the Transferring Shareholders as follows:

- (a) 2,000,000 Shares upon delivery to the Issuer of: (i) a certified amparo license, (ii) a valid certification confirming the completion of the cannabis seed importation and registration process and (iii) receipt of the delivery of certain imported licensed cannabis seeds; and
- (b) the remaining 2,000,000 Shares upon delivery to the Issuer of a valid license indicating that the imported cannabis seeds and genetics: (i) are registered in the National Seed Inspection and Certification Service registry and (ii) are authorized for commercial cultivation permitting domestic and foreign sales.

3.	Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:			
	(a)	Total aggregate consideration in Canadian dollars: <u>CAD\$4,838,000</u> (USD\$4,000,000, as converted to CAD on the date of the entering into of the Stock Transfer Agreement and based on the daily average exchange rate posted by the Bank of Canada for conversion of U.S. dollars into Canadian dollars on June 9, 2021).		
	(b)	Cash: N/A		
	(c)	Securities (including options, warrants etc.) and dollar value: 10,000,000 Shares with an aggregate deemed price of USD\$4,000,000, as converted to CAD on the date of the entering into of the Stock Transfer Agreement and based on the daily average exchange rate posted by the Bank of Canada for conversion of U.S. dollars into Canadian dollars on June 9, 2021. See response to Item #2, above.		
	(d)	Other: N/A .		
	(e)	Expiry date of options, warrants, etc. if any: N/A .		
	(f)	Exercise price of options, warrants, etc. if any: N/A		
	(g)	Work commitments: N/A .		
4.	State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).  The purchase price for the Transaction was determined via arm's length negotiations of the parties.			
5.	Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: <u>N/A.</u>			
6.	The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows: Filed on a confidential basis with the Canadian Securities Exchange.			

Name of Party (If not an individual, name all insiders of the Party)	Securities	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer <sup>(1)</sup>

Details of the steps taken by the Issuer to ensure that the vendor has title to the assets being acquired: The Issuer conducted a review corporate records of D9C to verify ownership of the share capital Transferring Shareholders and obtained contractual representations from Transferring Shareholders.					
Provide the following information for any agent's fee, commission, bonus of finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):					
(a)	Details of any dealer, agent, broker or other person receivir compensation in connection with the acquisition (name, and if corporation, identify persons owning or exercising voting controver 20% or more of the voting shares if known to the Issuer): N/A				
(b)	Cash N/A.				
(c)	Securities N/A.				
(d)	Other N/A.				
(e)	Expiry date of any options, warrants etc. N/A.				
(f)	Exercise price of any options, warrants etc. N/A.				
in conne	nether the sales agent, broker or other person receiving compensation of the acquisition is a Related Person or has any other hip with the Issuer and provide details of the relationship. N/A.				

14/7 \			

#### **Certificate Of Compliance**

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
- 2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
- 3. the Issuer has obtained the express written consent of each applicable individual to:
  - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
  - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
- 4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
- 5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated <u>June 16, 2021</u>	
	Bill Keating  Name of Director or Senior  Officer
	<u>"<i>Bill Keating</i>"</u> Signature
	Chief Operating Officer Official Capacity

#### Appendix A

#### PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, "CSE or the "Exchange") collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

•

- To determine whether an individual is suitable to be associated with a Listed Issuer:
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange's obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.